Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01095276 · ClinicalTrials.gov registry record · NA
Impact of Nebulized Dornase Alpha on Mechanically Ventilated Patients
A NA study of Atelectasis and Ventilation, Mechanical, sponsored by University of Medicine and Dentistry of New Jersey.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT01095276: Completed NA study of Atelectasis and Ventilation, Mechanical, sponsored by University of Medicine and Dentistry of New Jersey.
NCT01095276 is a NA study of Atelectasis and Ventilation, Mechanical that has completed, run by University of Medicine and Dentistry of New Jersey. The registered enrollment target is 30 participants, below the 226-participant average among 3 other Atelectasis trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01095276, a NA study of Atelectasis and Ventilation, Mechanical, has completed, sponsored by University of Medicine and Dentistry of New Jersey.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators hypothesized that dornase alpha, administered twice a day (BID) by in-line nebulizer, would improve oxygenation, compliance, and time to extubation in adult patients receiving mechanical ventilation.
Conditions Studied
Interventions
- DRUG Saline
- DRUG Pulmozyme (nebulized dornase alpha)
Study Locations (1)
New Jersey
- University of Medicine and Dentistry of New Jersey - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-11 |
| Est. Completion | 2006-01 |
| Phase | NA |
What the finished NCT01095276 record still lists
NCT01095276 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 226-participant average among 3 other Atelectasis trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Atelectasis appearing as the primary indexed condition, and to 2 interventions - of which Saline is the first listed.
NCT01095276 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT01095276 about?
NCT01095276 is a clinical study titled "Impact of Nebulized Dornase Alpha on Mechanically Ventilated Patients". The investigators hypothesized that dornase alpha, administered twice a day (BID) by in-line nebulizer, would improve oxygenation, compliance, and time to extubation in adult patients receiving mechanical ventilation.
What is the current status of trial NCT01095276?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2005-11. Estimated completion is 2006-01.
What conditions does trial NCT01095276 study?
This clinical trial studies the following conditions: Atelectasis, Ventilation, Mechanical.
What interventions are being tested in trial NCT01095276?
The interventions under investigation include: Saline (DRUG), Pulmozyme (nebulized dornase alpha) (DRUG).
Who is sponsoring clinical trial NCT01095276?
This trial is sponsored by University of Medicine and Dentistry of New Jersey, which has 88 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01095276 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atelectasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia